Reuters -- Europe's drug advisory agency backed Tigenix's (G9U.BR) cartilage treatment for EU approval, all but assuring the launch of the Belgian biomedical firm's first product and sending its shares sharply higher.
Reuters -- Europe's drug advisory agency backed Tigenix's (G9U.BR) cartilage treatment for EU approval, all but assuring the launch of the Belgian biomedical firm's first product and sending its shares sharply higher.
